ICU Medical (NASDAQ:ICUI) Price Target Increased to $198.00 by Analysts at KeyCorp

ICU Medical (NASDAQ:ICUI) had its target price upped by research analysts at KeyCorp from $147.00 to $198.00 in a report issued on Tuesday, Benzinga reports. The firm presently has an “overweight” rating on the medical instruments supplier’s stock. KeyCorp’s price target would suggest a potential upside of 9.82% from the company’s previous close.

Other equities research analysts have also recently issued reports about the company. Jefferies Financial Group started coverage on ICU Medical in a research note on Monday. They set a “hold” rating and a $183.00 price objective for the company. Needham & Company LLC restated a “hold” rating on shares of ICU Medical in a report on Thursday, October 10th. Raymond James boosted their price objective on shares of ICU Medical from $158.00 to $190.00 and gave the stock an “outperform” rating in a research note on Thursday, September 12th. Finally, StockNews.com upgraded shares of ICU Medical from a “hold” rating to a “buy” rating in a research note on Thursday, September 12th. Two equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $170.25.

ICU Medical Trading Up 0.9 %

NASDAQ:ICUI opened at $180.30 on Tuesday. The firm has a 50-day simple moving average of $166.59 and a 200-day simple moving average of $130.32. ICU Medical has a one year low of $78.28 and a one year high of $188.53. The firm has a market cap of $4.39 billion, a P/E ratio of -73.59 and a beta of 0.66. The company has a debt-to-equity ratio of 0.76, a quick ratio of 1.08 and a current ratio of 2.41.

ICU Medical (NASDAQ:ICUI) last issued its quarterly earnings data on Wednesday, August 7th. The medical instruments supplier reported $1.56 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.00 by $0.56. The company had revenue of $596.50 million for the quarter, compared to analyst estimates of $556.64 million. ICU Medical had a negative net margin of 3.07% and a positive return on equity of 5.01%. ICU Medical’s revenue was up 8.6% compared to the same quarter last year. During the same period last year, the company posted $1.58 earnings per share. Equities analysts anticipate that ICU Medical will post 3.76 EPS for the current fiscal year.

Insider Activity at ICU Medical

In other ICU Medical news, CEO Vivek Jain sold 12,000 shares of the business’s stock in a transaction that occurred on Friday, August 16th. The shares were sold at an average price of $156.04, for a total transaction of $1,872,480.00. Following the sale, the chief executive officer now owns 104,593 shares of the company’s stock, valued at approximately $16,320,691.72. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. In other ICU Medical news, CEO Vivek Jain sold 12,000 shares of ICU Medical stock in a transaction dated Friday, August 16th. The stock was sold at an average price of $156.04, for a total transaction of $1,872,480.00. Following the completion of the sale, the chief executive officer now owns 104,593 shares of the company’s stock, valued at approximately $16,320,691.72. The trade was a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, VP Virginia Ruth Sanzone sold 2,050 shares of the stock in a transaction dated Thursday, August 8th. The shares were sold at an average price of $144.11, for a total value of $295,425.50. Following the completion of the transaction, the vice president now directly owns 4,482 shares in the company, valued at $645,901.02. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 40,552 shares of company stock valued at $6,679,322 in the last three months. 6.70% of the stock is owned by insiders.

Hedge Funds Weigh In On ICU Medical

A number of institutional investors have recently bought and sold shares of ICUI. Vanguard Group Inc. increased its stake in shares of ICU Medical by 14.8% in the fourth quarter. Vanguard Group Inc. now owns 2,440,729 shares of the medical instruments supplier’s stock worth $243,438,000 after acquiring an additional 315,103 shares during the period. PNC Financial Services Group Inc. raised its stake in shares of ICU Medical by 7.8% during the 4th quarter. PNC Financial Services Group Inc. now owns 2,576 shares of the medical instruments supplier’s stock valued at $257,000 after buying an additional 187 shares during the last quarter. GAMMA Investing LLC lifted its holdings in shares of ICU Medical by 75.1% in the 1st quarter. GAMMA Investing LLC now owns 310 shares of the medical instruments supplier’s stock valued at $33,000 after buying an additional 133 shares during the period. BNP Paribas Financial Markets boosted its stake in shares of ICU Medical by 55.3% in the first quarter. BNP Paribas Financial Markets now owns 4,552 shares of the medical instruments supplier’s stock worth $489,000 after buying an additional 1,620 shares during the last quarter. Finally, Wakefield Asset Management LLLP purchased a new stake in shares of ICU Medical in the first quarter worth about $989,000. 96.10% of the stock is owned by hedge funds and other institutional investors.

About ICU Medical

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.